Akiram Therapeutics
PrivateLast Round
Grant
Nov 24, 2023
Est. Valuation
$12.31M
Total Funding Raised
$570,000
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Akiram Therapeutics is a biotechnology company that develops innovative and targeted molecular radiotherapy for patients with incurable cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Akiram Therapeutics Comparables
Compare Akiram Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| PreTT ApS | 90% | |
| Precirix | 86% | |
| Ariceum Therapeutics | 82% |
Akiram Therapeutics Funding Rounds
Historical fundraising activity
Key People
Founding team and executive leadership
Akiram Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Phase2Phase Biopharma | VC Round |
| Sciety | VC Round |
| 3T Invest | VC Round |
| Erling-Persson Foundation | Grant |
| Linc AB | VC Round |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 28, 2026
Monthly visitors increased 34% MoM.
- Oct 4, 2025
Attending EANM Congress 2025 in Barcelona from October 4-8.
Recent news
Latest coverage and updates
- recognized_asOct 13, 2026
At EANM 2026, Akiram Therapeutics's CD44v6-targeting platform earns a second study selection as a Top Rated Oral Presentation for preclinical research evaluating AKIR001 and a derived scFv antibody format in bladder cancer.
- attends_eventOct 13, 2026
Akiram Therapeutics is set to present the first clinical results for investigational candidate AKIR001 at the EANM 2026 congress in Austria on Oct 17th–21st '26.
- partners_withAug 20, 2026
On Aug 20th '26 in Sweden, Akiram Therapeutics and ITM SE partner through a supply agreement for non-carrier-added Lu-177 to support AKIR001's clinical development.
Akiram Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Akiram Therapeutics's valuation, stock price, and market status.
Is Akiram Therapeutics a public or private company?
Akiram Therapeutics is a private company.
What is the current stock price of Akiram Therapeutics?
Akiram Therapeutics is a private company, so its shares have no public market price. Caplight tracks Akiram Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Akiram Therapeutics worth (valuation)?
Akiram Therapeutics's valuation is estimated at $12.3M based on funding round data.
Can I buy Akiram Therapeutics stock?
Akiram Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Akiram Therapeutics's last funding round?
Akiram Therapeutics's most recent funding round was Grant on November 24, 2023.
Who are the main investors in Akiram Therapeutics?
Key investors in Akiram Therapeutics include Sciety.
Will Akiram Therapeutics IPO soon?
No public IPO plans have been announced for Akiram Therapeutics.
How can I track Akiram Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Akiram Therapeutics's shares on secondary markets.